001     154370
005     20240411115843.0
024 7 _ |a 10.1186/s13024-020-00407-2
|2 doi
024 7 _ |a pmid:33032659
|2 pmid
024 7 _ |a pmc:PMC7545547
|2 pmc
024 7 _ |a altmetric:92036329
|2 altmetric
037 _ _ |a DZNE-2021-00223
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Franzmeier, Nicolai
|0 0000-0001-9736-2283
|b 0
245 _ _ |a Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.
260 _ _ |a London
|c 2020
|b Biomed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1712750767_11352
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 1750-1326 not unique: **3 hits**.
520 _ _ |a The Apolipoprotein E ε4 allele (i.e. ApoE4) is the strongest genetic risk factor for sporadic Alzheimer's disease (AD). TREM2 (i.e. Triggering receptor expressed on myeloid cells 2) is a microglial transmembrane protein brain that plays a central role in microglia activation in response to AD brain pathologies. Whether higher TREM2-related microglia activity modulates the risk to develop clinical AD is an open question. Thus, the aim of the current study was to assess whether higher sTREM2 attenuates the effects of ApoE4-effects on future cognitive decline and neurodegeneration.We included 708 subjects ranging from cognitively normal (CN, n = 221) to mild cognitive impairment (MCI, n = 414) and AD dementia (n = 73) from the Alzheimer's disease Neuroimaging Initiative. We used linear regression to test the interaction between ApoE4-carriage by CSF-assessed sTREM2 levels as a predictor of longitudinally assessed cognitive decline and MRI-assessed changes in hippocampal volume changes (mean follow-up of 4 years, range of 1.7-7 years).Across the entire sample, we found that higher CSF sTREM2 at baseline was associated with attenuated effects of ApoE4-carriage (i.e. sTREM2 x ApoE4 interaction) on longitudinal global cognitive (p = 0.001, Cohen's f2 = 0.137) and memory decline (p = 0.006, Cohen's f2 = 0.104) as well as longitudinally assessed hippocampal atrophy (p = 0.046, Cohen's f2 = 0.089), independent of CSF markers of primary AD pathology (i.e. Aβ1-42, p-tau181). While overall effects of sTREM2 were small, exploratory subanalyses stratified by diagnostic groups showed that beneficial effects of sTREM2 were pronounced in the MCI group.Our results suggest that a higher CSF sTREM2 levels are associated with attenuated ApoE4-related risk for future cognitive decline and AD-typical neurodegeneration. These findings provide further evidence that TREM2 may be protective against the development of AD.
536 _ _ |a 341 - Molecular Signaling (POF3-341)
|0 G:(DE-HGF)POF3-341
|c POF3-341
|f POF III
|x 0
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 1
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a ApoE4
|2 Other
650 _ 7 |a Cognitive decline
|2 Other
650 _ 7 |a Microglial activation
|2 Other
650 _ 7 |a Neurodegeneration
|2 Other
650 _ 7 |a sTREM2
|2 Other
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Apolipoprotein E4: genetics
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: genetics
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: pathology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Genetic Predisposition to Disease
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Membrane Glycoproteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Nerve Degeneration: pathology
|2 MeSH
650 _ 2 |a Receptors, Immunologic
|2 MeSH
700 1 _ |a Suárez-Calvet, M.
|b 1
700 1 _ |a Frontzkowski, Lukas
|b 2
700 1 _ |a Moore, Annah
|b 3
700 1 _ |a Hohman, Timothy J
|b 4
700 1 _ |a Morenas-Rodriguez, Estrella
|b 5
700 1 _ |a Nuscher, Brigitte
|b 6
700 1 _ |a Shaw, Leslie
|b 7
700 1 _ |a Trojanowski, John Q
|b 8
700 1 _ |a Dichgans, Martin
|0 P:(DE-2719)2000030
|b 9
|u dzne
700 1 _ |a Kleinberger, Gernot
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Haass, Christian
|0 P:(DE-2719)2202037
|b 11
|u dzne
700 1 _ |a Ewers, Michael
|0 P:(DE-2719)9000543
|b 12
|e Last author
|u dzne
700 1 _ |a Initiative, Alzheimer’s Disease Neuroimaging
|0 P:(DE-HGF)0
|b 13
|e Collaboration Author
700 1 _ |a Weiner, Michael
|b 14
700 1 _ |a Aisen, Paul
|b 15
700 1 _ |a Novak, Gerald
|b 16
700 1 _ |a Green, Robert C
|b 17
700 1 _ |a Montine, Tom
|b 18
700 1 _ |a Petersen, Ronald
|b 19
700 1 _ |a Gamst, Anthony
|b 20
700 1 _ |a Thomas, Ronald G
|b 21
700 1 _ |a Donohue, Michael
|b 22
700 1 _ |a Walter, Sarah
|b 23
700 1 _ |a Gessert, Devon
|b 24
700 1 _ |a Sather, Tamie
|b 25
700 1 _ |a Beckett, Laurel
|b 26
700 1 _ |a Harvey, Danielle
|b 27
700 1 _ |a Kornak, John
|b 28
700 1 _ |a Jack, Clifford R
|b 29
700 1 _ |a Dale, Anders
|b 30
700 1 _ |a Bernstein, Matthew
|b 31
700 1 _ |a Felmlee, Joel
|b 32
700 1 _ |a Fox, Nick
|b 33
700 1 _ |a Thompson, Paul
|b 34
700 1 _ |a Schuff, Norbert
|b 35
700 1 _ |a Alexander, Gene
|b 36
700 1 _ |a DeCarli, Charles
|b 37
700 1 _ |a Jagust, William
|b 38
700 1 _ |a Bandy, Dan
|b 39
700 1 _ |a Koeppe, Robert A
|b 40
700 1 _ |a Foster, Norm
|b 41
700 1 _ |a Reiman, Eric M
|b 42
700 1 _ |a Chen, Kewei
|b 43
700 1 _ |a Mathis, Chet
|b 44
700 1 _ |a Morris, John
|b 45
700 1 _ |a Cairns, Nigel J
|b 46
700 1 _ |a Taylor-Reinwald, Lisa
|b 47
700 1 _ |a Trojanowki, J. Q.
|b 48
700 1 _ |a Shaw, Les
|b 49
700 1 _ |a Lee, Virginia M Y
|b 50
700 1 _ |a Korecka, Magdalena
|b 51
700 1 _ |a Toga, Arthur W
|b 52
700 1 _ |a Crawford, Karen
|b 53
700 1 _ |a Neu, Scott
|b 54
700 1 _ |a Saykin, Andrew J
|b 55
700 1 _ |a Foroud, Tatiana M
|b 56
700 1 _ |a Potkin, Steven
|b 57
700 1 _ |a Shen, Li
|b 58
700 1 _ |a Kachaturian, Zaven
|b 59
700 1 _ |a Frank, Richard
|b 60
700 1 _ |a Snyder, Peter J
|b 61
700 1 _ |a Molchan, Susan
|b 62
700 1 _ |a Kaye, Jeffrey
|b 63
700 1 _ |a Dolen, Sara
|b 64
700 1 _ |a Quinn, Joseph
|b 65
700 1 _ |a Schneider, Lon S
|b 66
700 1 _ |a Pawluczyk, Sonia
|b 67
700 1 _ |a Spann, Bryan M
|b 68
700 1 _ |a Brewer, James
|b 69
700 1 _ |a Vanderswag, Helen
|b 70
700 1 _ |a Heidebrink, Judith L
|b 71
700 1 _ |a Lord, Joanne L
|b 72
700 1 _ |a Johnson, Kris
|b 73
700 1 _ |a Doody, Rachelle S
|b 74
700 1 _ |a Villanueva-Meyer, Javier
|b 75
700 1 _ |a Chowdhury, Munir
|b 76
700 1 _ |a Stern, Yaakov
|b 77
700 1 _ |a Honig, Lawrence S
|b 78
700 1 _ |a Bell, Karen L
|b 79
700 1 _ |a Morris, John C
|b 80
700 1 _ |a Mintun, Mark A
|b 81
700 1 _ |a Schneider, Stacy
|b 82
700 1 _ |a Marson, Daniel
|b 83
700 1 _ |a Griffith, Randall
|b 84
700 1 _ |a Clark, David
|b 85
700 1 _ |a Grossman, Hillel
|b 86
700 1 _ |a Mitsis, Effie
|b 87
700 1 _ |a Romirowsky, Aliza
|b 88
700 1 _ |a deToledo-Morrell, Leyla
|b 89
700 1 _ |a Shah, Raj C
|b 90
700 1 _ |a Duara, Ranjan
|b 91
700 1 _ |a Varon, Daniel
|b 92
700 1 _ |a Roberts, Peggy
|b 93
700 1 _ |a Albert, Marilyn
|b 94
700 1 _ |a Onyike, Chiadi
|b 95
700 1 _ |a Kielb, Stephanie
|b 96
700 1 _ |a Rusinek, Henry
|b 97
700 1 _ |a de Leon, Mony J
|b 98
700 1 _ |a Glodzik, Lidia
|b 99
700 1 _ |a Doraiswamy, P Murali
|b 100
700 1 _ |a Petrella, Jeffrey R
|b 101
700 1 _ |a Arnold, Steven E
|b 102
700 1 _ |a Karlawish, Jason H
|b 103
700 1 _ |a Wolk, David
|b 104
700 1 _ |a Smith, Charles D
|b 105
700 1 _ |a Jicha, Greg
|b 106
700 1 _ |a Hardy, Peter
|b 107
700 1 _ |a Lopez, Oscar L
|b 108
700 1 _ |a Oakley, Mary Ann
|b 109
700 1 _ |a Simpson, Donna M
|b 110
700 1 _ |a Ismail, M Saleem
|b 111
700 1 _ |a Brand, Connie
|b 112
700 1 _ |a Mulnard, Ruth A
|b 113
700 1 _ |a Thai, Gaby
|b 114
700 1 _ |a Mc-Adams-Ortiz, Catherine
|b 115
700 1 _ |a Diaz-Arrastia, Ramon
|b 116
700 1 _ |a Martin-Cook, Kristen
|b 117
700 1 _ |a DeVous, Michael
|b 118
700 1 _ |a Levey, Allan I
|b 119
700 1 _ |a Lah, James J
|b 120
700 1 _ |a Cellar, Janet S
|b 121
700 1 _ |a Burns, Jeffrey M
|b 122
700 1 _ |a Anderson, Heather S
|b 123
700 1 _ |a Swerdlow, Russell H
|b 124
700 1 _ |a Bartzokis, George
|b 125
700 1 _ |a Silverman, Daniel H S
|b 126
700 1 _ |a Lu, Po H
|b 127
700 1 _ |a Apostolova, Liana
|b 128
700 1 _ |a Graff-Radford, Neill R
|b 129
700 1 _ |a Parfitt, Francine
|b 130
700 1 _ |a Johnson, Heather
|b 131
700 1 _ |a Farlow, Martin
|b 132
700 1 _ |a Herring, Scott
|b 133
700 1 _ |a Hake, Ann M
|b 134
700 1 _ |a van Dyck, Christopher H
|b 135
700 1 _ |a Carson, Richard E
|b 136
700 1 _ |a MacAvoy, Martha G
|b 137
700 1 _ |a Chertkow, Howard
|b 138
700 1 _ |a Bergman, Howard
|b 139
700 1 _ |a Hosein, Chris
|b 140
700 1 _ |a Black, Sandra
|b 141
700 1 _ |a Stefanovic, Bojana
|b 142
700 1 _ |a Caldwell, Curtis
|b 143
700 1 _ |a Hsiung, Ging-Yuek Robin
|b 144
700 1 _ |a Feldman, Howard
|b 145
700 1 _ |a Assaly, Michele
|b 146
700 1 _ |a Kertesz, Andrew
|b 147
700 1 _ |a Rogers, John
|b 148
700 1 _ |a Trost, Dick
|b 149
700 1 _ |a Bernick, Charles
|b 150
700 1 _ |a Munic, Donna
|b 151
700 1 _ |a Wu, Chuang-Kuo
|b 152
700 1 _ |a Johnson, Nancy
|b 153
700 1 _ |a Mesulam, Marsel
|b 154
700 1 _ |a Sadowsky, Carl
|b 155
700 1 _ |a Martinez, Walter
|b 156
700 1 _ |a Villena, Teresa
|b 157
700 1 _ |a Turner, Raymond Scott
|b 158
700 1 _ |a Johnson, Kathleen
|b 159
700 1 _ |a Reynolds, Brigid
|b 160
700 1 _ |a Sperling, Reisa A
|b 161
700 1 _ |a Frey, Meghan
|b 162
700 1 _ |a Johnson, Keith A
|b 163
700 1 _ |a Rosen, Allyson
|b 164
700 1 _ |a Tinklenberg, Jared
|b 165
700 1 _ |a Ashford, Wes
|b 166
700 1 _ |a Sabbagh, Marwan
|b 167
700 1 _ |a Belden, Christine
|b 168
700 1 _ |a Jacobson, Sandra
|b 169
700 1 _ |a Killiany, Ronald
|b 170
700 1 _ |a Norbash, Alexander
|b 171
700 1 _ |a Nair, Anil
|b 172
700 1 _ |a Obisesan, Thomas O
|b 173
700 1 _ |a Wolday, Saba
|b 174
700 1 _ |a Bwayo, Salome K
|b 175
700 1 _ |a Lerner, Alan
|b 176
700 1 _ |a Hudson, Leon
|b 177
700 1 _ |a Ogrocki, Paula
|b 178
700 1 _ |a Fletcher, Evan
|b 179
700 1 _ |a Carmichael, Owen
|b 180
700 1 _ |a Kittur, Smita
|b 181
700 1 _ |a Borrie, Michael
|b 182
700 1 _ |a Lee, T-Y
|b 183
700 1 _ |a Bartha, Rob
|b 184
700 1 _ |a Johnson, Sterling
|b 185
700 1 _ |a Asthana, Sanjay
|b 186
700 1 _ |a Carlsson, Cynthia M
|b 187
700 1 _ |a Potkin, Steven G
|b 188
700 1 _ |a Preda, Adrian
|b 189
700 1 _ |a Nguyen, Dana
|b 190
700 1 _ |a Tariot, Pierre
|b 191
700 1 _ |a Fleisher, Adam
|b 192
700 1 _ |a Reeder, Stephanie
|b 193
700 1 _ |a Bates, Vernice
|b 194
700 1 _ |a Capote, Horacio
|b 195
700 1 _ |a Rainka, Michelle
|b 196
700 1 _ |a Hendin, Barry A
|b 197
700 1 _ |a Scharre, Douglas W
|b 198
700 1 _ |a Kataki, Maria
|b 199
700 1 _ |a Zimmerman, Earl A
|b 200
700 1 _ |a Celmins, Dzintra
|b 201
700 1 _ |a Brown, Alice D
|b 202
700 1 _ |a Hosp, Hartford
|b 203
700 1 _ |a Pearlson, Godfrey D
|b 204
700 1 _ |a Blank, Karen
|b 205
700 1 _ |a Anderson, Karen
|b 206
700 1 _ |a Santulli, Robert B
|b 207
700 1 _ |a Schwartz, Eben S
|b 208
700 1 _ |a Williamson, Jeff D
|b 209
700 1 _ |a Sink, Kaycee M
|b 210
700 1 _ |a Watkins, Franklin
|b 211
700 1 _ |a Ott, Brian R
|b 212
700 1 _ |a Querfurth, Henry
|b 213
700 1 _ |a Tremont, Geoffrey
|b 214
700 1 _ |a Salloway, Stephen
|b 215
700 1 _ |a Malloy, Paul
|b 216
700 1 _ |a Correia, Stephen
|b 217
700 1 _ |a Rosen, Howard J
|b 218
700 1 _ |a Miller, Bruce L
|b 219
700 1 _ |a Mintzer, Jacobo
|b 220
700 1 _ |a Longmire, Crystal Flynn
|b 221
700 1 _ |a Spicer, Kenneth
|b 222
773 _ _ |a 10.1186/s13024-020-00407-2
|g Vol. 15, no. 1, p. 57
|0 PERI:(DE-600)2244557-2
|n 1
|p 57
|t Molecular neurodegeneration
|v 15
|y 2020
|x 1750-1326
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/154370/files/DZNE-2021-00223.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/154370/files/DZNE-2021-00223.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:154370
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2000030
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2202037
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9000543
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-341
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Molecular Signaling
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 2
913 2 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-23
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-09-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-09-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-23
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b MOL NEURODEGENER : 2021
|d 2022-11-23
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL NEURODEGENER : 2021
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-08-24T06:30:04Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-08-24T06:30:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-23
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-23
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-23
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-08
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1110008
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21